Core F: Biomarker Core

核心 F：生物标志物核心

基本信息

批准号：
10652573
负责人：
LEE E. GOLDSTEIN
金额：
$ 33.13万
依托单位：
BOSTON UNIVERSITY MEDICAL CAMPUS
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-08-15 至 2026-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10652573
关键词：
Address Ally Alzheimer&apos s Disease Alzheimer&apos s disease related dementia Alzheimer’s disease biomarker Amyloid Amyloid beta-Protein Atrophic Biological Markers Biometry Blood Boston Brain imaging Cells Cerebrum Clinical Clinical Research Collaborations Communities Data Dementia Detection Development Diagnosis Differential Diagnosis Disease Doctor of Medicine Doctor of Philosophy Early Diagnosis Early Intervention Early treatment Education Emerging Technologies Faculty Generations Goals Hippocampus Human Image Imaging Techniques Institution International Ligand Binding Light Liquid substance MRI Scans Magnetic Resonance Imaging Measures Mentorship Mission Molecular Profiling Monitor National Institute on Alcohol Abuse and Alcoholism Nerve Degeneration Neurobehavioral Manifestations Neurodegenerative Disorders Neurons Participant Peptides Plasma Positron-Emission Tomography Postdoctoral Fellow Process Protocols documentation Qualifying Research Research Personnel Resources Risk Assessment Scientist Serum Specimen Staging Targeted Research Testing Therapeutic Thick Training United States National Institutes of Health Universities Update Ventricular accurate diagnosis biomarker development biomarker discovery biomarker validation brain volume chronic traumatic encephalopathy clinical development cohort cost effective data management data sharing early-career faculty education research entorhinal cortex exosome experience genetic profiling improved insight interest member multimodality neurofilament neuroimaging neuroimaging marker neuropathology next generation normal aging novel personalized medicine pre-clinical prevent research clinical testing response statistics tau Proteins tau-1 white matter

项目摘要

Biomarkers provide important information for early detection, differential diagnosis, and disease monitoring of Alzheimer’s disease (AD) and AD-related dementias (ADRDs), including chronic traumatic encephalopathy (CTE). The newly established Biomarker Core of the Boston University Alzheimer’s Disease Research Center (BU ADRC) will be led by three clinician-scientists with experience in biomarker development and validation: Lee Goldstein, M.D., Ph.D. and Wendy Qiu, M.D., Ph.D., who will serve as co-leaders, and Ronald Killiany, Ph.D., who will lead the neuroimaging component. The Biomarker Core will leverage their expertise and existing institutional resources to focus on fluid biospecimen and neuroimaging biomarkers relevant to Alzheimer’s disease (AD) and related dementias (ADRD), including chronic traumatic encephalopathy (CTE). The goal of the Biomarker Core is to collaborate with other cores and centralize biomarker initiatives to support the BU ADRC mission to improve early and accurate diagnosis, differentiation, and monitoring of AD and ADRDs, including CTE. The new Biomarker Core will bank, distribute, and analyze fluid biospecimens and neuroimaging data for shared use by investigators within and outside the BU ADRC and allied national consortia. We will focus on established biofluid and neuroimaging biomarkers (Amyloid-Tau-Neurodegeneration A/T/N NIA-AA Research Framework) with the goal of identifying differences between AD and ADRDs. The Core will also conduct discovery-based development of novel emerging biofluid and neuroimaging biomarkers to enable earlier and more accurate detection, differential diagnosis, staging, and tracking of AD and ADRDs across the disease spectrum. Four Specific Aims are proposed. Aim 1: Process, bank, and distribute fluid biospecimens and neuroimaging data. Aim 2: Measure and analyze established biomarkers (A/T/N NIA-AA Research Framework). Aim 3: Conduct discovery and development of emerging biomarkers, including analysis of blood-derived exosomes and multimodal computational strategies for neuroimaging data. Aim 4: Train next-generation AD biomarker and neuroimaging research leaders. We anticipate that the new Biomarker Core will strengthen BU ADRC research, promote sharing of fluid and neuroimaging biomarker resources, harmonize with efforts to advance national AD/ADRD initiatives, and provide new new insights and biometrics for personalized medicine approaches to diagnose, treat, and prevent AD and ADRD.

生物标志物为早期检测，鉴别诊断和疾病监测提供了重要信息阿尔茨海默氏病（AD）和与广告相关的痴呆症（ADRDS），含有慢性创伤性脑病（CTE）。（BU ADRC）将由三位具有生物标志物开发和验证经验的临床医生领导：Leee M.D. Goldstein博士和Wendy Qiu，M.D.，Ph.D。谁将带领神经成像组成部分。与阿尔茨海默氏症相关的液体生物测量和神经标志物生物标志物的精致资源疾病（AD）和相关痴呆症（ADRD），包括慢性创伤性脑病（CTE）。生物标志物核心合作Wither Cores并集中生物标志物计划，以支持BU ADRC 提高早期和准确诊断，差异化以及对AD和ADRD的监测的使命，包括 CTE。 BU ADRC和Allied National Consortia内外的调查人员共享。已建立的生物流体和神经影像学生物标志物框架）目的是确定AD和ADRD之间的差异。基于发现的新型新兴和神经影像制定生物标志物的开发能够早期启用和更准确的检测，鉴别诊断，分期和AD的跟踪以及疾病的adross Spectrum提出了四个特定目标。神经成像数据2：测量和分析已建立的生物标志物（A/T/NIA-AA研究框架）。目标3：进行新兴生物标志物的发现和开发，包括对血液的分析神经影像数据的外泌体和多模式计算策略4：训练下一代广告生物标志物和神经成像研究领导者。 ADRC研究，促进流体和神经成像生物标志物资源的共享，与范围协调推进国家广告/ADRD计划，并为个性化医学提供新的新见解和生物识别技术诊断，治疗和预防AD和ADRD的方法。